Contact Us
EN
/
中
Company
People
Pipeline
Our Pipeline
Izokibep (IMG-020)
Partnering
In-Licensing
News & Events
careers
CONTACT US
EN
/
中
Borderless Innovation
guided by
Global Intelligence
About Inmagene
Learn more
Our pipeline
Inmagene has a robust and growing pipeline of nearly 20 drug candidates, focused on treating immunological diseases.
Learn more
Clinical Trials
Inmagene is enrolling patients for a Phase 2 clinical study of Izokibep for Ankylosing Spondylitis in the US.
Learn more
Partnering
Inmagene has formed strategic partnerships with Affibody AB, HUTCHMED (Nasdaq/AIM: HCM) and Kissei to develop and commercialize highly innovative drug candidates.
Inmagene has several assets with strong differentiations available for Partnering.
Learn more
News and Events
View all news
